The score is not available for this stock. This could be because (a) the market cap of the... Read More
Value score
The score is not available for this stock. This could be because (a) the market cap of the... Read More
Price Momentum score
The score is not available for this stock. This could be because (a) the market cap of the... Read More
QVM score
The score is not available for this stock. This could be because (a) the market cap of the... Read More
PDPL Key Metrics
PDPL Share Price
Stock Analysis
Snapshot
Shareholding Pattern
Bulk, Block & Insider Trades
Corporate Actions
Company Profile
PDPL Share Price
PDPL
1 Week returns: -
1 Month returns: -
1 Year returns: -
3 Years CAGR: -
5 Years CAGR: -
Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
PDPL Stock Analysis
Views
Red Flags
Positive
Not enough talking point with positive stance
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Neutral
Not enough talking point with neutral stance
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
PDPL Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
PDPL Bulk, Block & Insider Trades
PDPL Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Bonus(1 new shares for 3 existing shares)AGM 15 September 2010. BOD 02 September 2010. Book closure end date 15 September 2010. Ex-date: 13th Sep 2010 Announced on: 2nd Sep 2010
Bonus(1 new shares for 1 existing shares)Bonus issue of 5600000 securities Ex-date: 2nd Nov 2007 Announced on: 4th Sep 2007
Company Profile
Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Car... Read More
Key personnel
Shri. Manohar Lal GuptaD
Non-Executive Chairman of the Board
Shri. Vinod Kumar GuptaD
Managing Director, Executive Director
Shri. Govind Das GargD
Whole-time Director
Shree Ganesh Chambers
Company Secretary
Shri. Anil MittalD
Non-Executive Director
Shri. Manish VermaD
Additional Independent Director
Mrs. Chhaya GuptaD
Additional Non-Executive Independent Woman Director
Shri. Dharam Pal KhannaD
Independent Non-Executive Director
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Parenteral Drugs (India) Ltd.?
The current share price of Parenteral Drugs (India) Ltd. is ₹ 3.15 as of 09 Jan 2026.
What is the PE ratio of Parenteral Drugs (India) Ltd.?
The Price-to-Earnings (PE) ratio of Parenteral Drugs (India) Ltd. is - as of the latest financial data.
What is the ROE and ROCE of Parenteral Drugs (India) Ltd.?
Parenteral Drugs (India) Ltd. has a Return on Equity (ROE) of - and a Return on Capital Employed (ROCE) of - as per the latest financial reports.
What is the market cap of Parenteral Drugs (India) Ltd.?
The market capitalization of Parenteral Drugs (India) Ltd. stands at ₹ 9.39 Cr.
What is the dividend yield of Parenteral Drugs (India) Ltd.?
The dividend yield of Parenteral Drugs (India) Ltd. is - based on the current market price.
What is the RSI of Parenteral Drugs (India) Ltd.?
The Relative Strength Index (RSI) of Parenteral Drugs (India) Ltd. is 99.99.
What is the FII and DII holding in Parenteral Drugs (India) Ltd.?
Foreign Institutional Investors (FII) hold - and Domestic Institutional Investors (DII) hold - of Parenteral Drugs (India) Ltd. shares.
What sector does Parenteral Drugs (India) Ltd. belong to?
Parenteral Drugs (India) Ltd. operates in the Healthcare sector.
What is the beta of Parenteral Drugs (India) Ltd. stock?
The beta of Parenteral Drugs (India) Ltd. stock is -0.37, indicating its volatility relative to the broader market.
